U.S. markets closed
  • S&P Futures

    4,159.25
    -24.25 (-0.58%)
     
  • Dow Futures

    34,585.00
    -83.00 (-0.24%)
     
  • Nasdaq Futures

    13,205.50
    -151.25 (-1.13%)
     
  • Russell 2000 Futures

    2,187.50
    -22.10 (-1.00%)
     
  • Crude Oil

    64.52
    -0.40 (-0.62%)
     
  • Gold

    1,836.30
    -1.30 (-0.07%)
     
  • Silver

    27.36
    -0.13 (-0.46%)
     
  • EUR/USD

    1.2136
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6020
    +0.0250 (+1.59%)
     
  • Vix

    19.66
    +2.97 (+17.80%)
     
  • GBP/USD

    1.4122
    +0.0000 (+0.00%)
     
  • USD/JPY

    108.9560
    +0.1150 (+0.11%)
     
  • BTC-USD

    55,518.93
    -3,249.24 (-5.53%)
     
  • CMC Crypto 200

    1,456.79
    -104.51 (-6.69%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    28,843.47
    -674.87 (-2.29%)
     

Here's Why We're Watching Destiny Pharma's (LON:DEST) Cash Burn Situation

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Just because a business does not make any money, does not mean that the stock will go down. For example, Destiny Pharma (LON:DEST) shareholders have done very well over the last year, with the share price soaring by 412%. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So notwithstanding the buoyant share price, we think it's well worth asking whether Destiny Pharma's cash burn is too risky. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for Destiny Pharma

When Might Destiny Pharma Run Out Of Money?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Destiny Pharma last reported its balance sheet in December 2020, it had zero debt and cash worth UK£9.7m. Importantly, its cash burn was UK£7.8m over the trailing twelve months. Therefore, from December 2020 it had roughly 15 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Destiny Pharma's Cash Burn Changing Over Time?

Although Destiny Pharma reported revenue of UK£12k last year, it didn't actually have any revenue from operations. That means we consider it a pre-revenue business, and we will focus our growth analysis on cash burn, for now. During the last twelve months, its cash burn actually ramped up 67%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can Destiny Pharma Raise More Cash Easily?

Given its cash burn trajectory, Destiny Pharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of UK£77m, Destiny Pharma's UK£7.8m in cash burn equates to about 10% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

How Risky Is Destiny Pharma's Cash Burn Situation?

On this analysis of Destiny Pharma's cash burn, we think its cash burn relative to its market cap was reassuring, while its increasing cash burn has us a bit worried. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. Separately, we looked at different risks affecting the company and spotted 5 warning signs for Destiny Pharma (of which 2 are a bit unpleasant!) you should know about.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.